BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24432794)

  • 1. The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.
    Theodotou C; Shah AH; Hayes S; Bregy A; Johnson JN; Aziz-Sultan MA; Komotar RJ
    Br J Neurosurg; 2014 Aug; 28(4):438-46. PubMed ID: 24432794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
    Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
    Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
    Zhu P; Zhu JJ
    Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
    BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of brachytherapy in the treatment of glioblastoma multiforme.
    Barbarite E; Sick JT; Berchmans E; Bregy A; Shah AH; Elsayyad N; Komotar RJ
    Neurosurg Rev; 2017 Apr; 40(2):195-211. PubMed ID: 27180560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme.
    Burkhardt JK; Shin BJ; Schlaff CD; Riina H; Boockvar JA
    J Exp Ther Oncol; 2011; 9(3):183-6. PubMed ID: 22070049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
    Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme.
    Kase M; Adamson A; Saretok M; Minajeva A; Vardja M; Jõgi T; Asser T; Jaal J
    J Neurosurg Sci; 2016 Dec; 60(4):417-23. PubMed ID: 25215582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
    Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
    Kanner AA; Wong ET; Villano JL; Ram Z;
    Semin Oncol; 2014 Oct; 41 Suppl 6():S25-34. PubMed ID: 25213871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.